ClinicalTrials.gg
CompletedNCT05619497Updated Nov 4, 2026Results posted

The OPENS Trial: Offering Women PrEP (Aim 2)

An interventional study of Clinic-wide Trainings and Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST) in Human Immunodeficiency Virus, Human Immunodeficiency Virus Transmission and Sexually Transmitted Diseases, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Primary conditionSexually Transmitted DiseasesRegistry: Acquired Immunodeficiency SyndromeReclassifiedWhy we changed it
Registry
Acquired Immunodeficiency Syndrome — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sexually Transmitted Diseases
Why
  1. The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Sexually Transmitted Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Other

How we know

Updated Nov 4, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
141
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sexually Transmitted Diseases by University of California, San Francisco — 1 open to participants now, 1 under way, none of them phase 3. Sexually Transmitted Diseases · University of California, San Francisco.

Enrollment
8th of 10
141 · median 509
Started
2022
the only one that year
No phase
8 of 13
1 open now
Registered
12th of 13
by date

Among the 13 studies in Sexually Transmitted Diseases by University of California, San Francisco, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 8 with no phase, and was the 12th registered.

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

Browse Sexually Transmitted Diseases studies →

Open to participants now

1 of the 13 studies in Sexually Transmitted Diseases by University of California, San Francisco is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sexually Transmitted Diseases by University of California, San Francisco, or all of them as a file.
02

Study summary

To address the significant barriers to pre-exposure prophylaxis (PrEP) implementation for cisgender women and address racial inequities in HIV prevention in the United States (US), a novel approach that accounts for multilevel influences is necessary. This study is the second part (Aim 2) of a multi-component project and involves a patient- and clinic-level intervention in a public health reproductive health clinic and an STI clinic in Duval County Florida, where most patients are women of color. The area has one of the highest HIV incidence rates among women in the US. The investigators developed 1) a tablet-based decision support tool (DST) that helps users learn about HIV vulnerabilities and HIV prevention strategies to inform how they consider options for reducing their likelihood of acquiring HIV, and 2) clinic-wide trainings regarding shared decision making and trauma informed care. In Aim 1 (previously completed), participants were randomized to viewing an HIV prevention DST in a clinic that had not received clinic-wide trainings. In Aim 2 (the present study), there will be two phases. In the first phase, participants will receive care at the clinics following training; the DST will not be used. In the second phase, in addition to being seen at a clinic-site that has experienced the training, participants will use the DST before their visit. Participants will be surveyed about experiences with HIV prevention counseling, intentions about using HIV prevention, and DST use (among those in the active arm in the second phase). A subset of participants, individuals who self-identify as Black or Latinx, will also complete a post-clinic visit interview. The investigators will assess whether participants initiated an HIV prevention method three months following their initial visit. The main outcomes will include a quantitative and qualitative assessment of PrEP or other HIV prevention use, decisional certainty, and satisfaction with information about HIV prevention options.

Read the detailed description

Although 13% of the U.S. female population is Black, 60% of new HIV diagnoses in U.S. women occur among Black women. The South is the epicenter of the U.S. HIV epidemic, including in women, and Black Southern women are disproportionately affected: Black women account for 69% of new HIV diagnoses in women in the South. As the first highly effective, discrete, woman-controlled HIV prevention method, oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine radically expands HIV prevention options for women. However, uptake of PrEP in U.S. women has lagged, particularly among groups most affected by HIV.

PrEP cascades outline the necessary steps for accessing PrEP, including screening and identifying eligible individuals, linkage to care, prescription, and initiation of PrEP. Data suggest there are multilevel barriers related to the process of screening for HIV risk in women and identifying potential PrEP candidates that may drive a significant drop off early in the PrEP cascade for women. Women report feeling judged by risk assessment questions and experience stigma around disclosing sexual practices. As a result, if screening is required to educate patients about PrEP - as is true in most clinical settings - many women for whom PrEP is appropriate may never learn about PrEP. Further, women have low levels of knowledge about HIV risk and HIV prevention options, and therefore will not seek out PrEP services themselves. Lastly, there is often limited time to educate patients in busy clinics. By offering education to all women about vulnerabilities to HIV as well as information about HIV prevention methods including PrEP, at-risk women can circumvent these multifactorial barriers and request PrEP. Electronic decision support tools (DST), which have been used with success in a range of healthcare contexts including contraception, provide an efficient and private mechanism for this information-sharing step.

The study team developed a tablet-based tool that is designed to provide universal PrEP education and facilitate women's agency to identify their own risks and interest in PrEP. It was refined with iterative feedback from patient and community stakeholders and finalized based on cognitive testing.

The DST provides information about vulnerabilities to HIV, and emphasizes the variable and individual nature of baseline risk. It provides information on the core characteristics of different HIV prevention methods, and then the opportunity to explore these characteristics in depth, including efficacy, safety and side effects. The user chooses the level of information that they wish to receive through the interactive interface, allowing for an individualized experience. Upon reaching the end of the tool, information on the tablet suggests that women ask their provider about HIV prevention methods they are interested in using, based on their preferences for method characteristics, and their questions to facilitate deliberation with the provider. The DST takes approximately 10 minutes to complete. A decision support tool was chosen as a key component of the study following its proven effectiveness in offering contraceptive options to patients. The HIV prevention DST was tested in Aim 1 of this study: participants were randomized to viewing the DST or not, prior to receiving usual care.

Additionally, the study team recognizes the importance of receiving health information from a trusted source, such as health care providers or health educators, when making important health decisions. Therefore, this study (Aim 2) will offer and assess the effects of a combined intervention of the DST following a clinic-wide training on shared decision making and trauma-informed care. Shared decision making is an effective strategy to offer information and services to patients as it allows the health care provider to share their clinical knowledge and expertise while partnering with the patient to elicit their experiential knowledge, needs and preferences. Through partnership between a patient and provider, the patient can make an informed decision about HIV prevention and other health needs that align with their values and desires and can result in greater adherence to the prevention or treatment options and satisfaction with care. The training will also include information about trauma-informed approaches to deliver health care in a person-centered and affirming manner. This training will highlight how many people, particularly those vulnerable to HIV due to intersecting oppressions, carry traumas that impact their exposure to health issues and the resources needed to mitigate these harms. It is critical that health care providers and health professionals are aware of intersecting forms of oppression that create trauma, including those that the medical profession create and perpetuate. A combined approach of shared decision making at the interpersonal level and trauma informed care at the clinic-level is an equity-oriented strategy to offering HIV prevention information to women in the Southeastern U.S. who are disproportionately impacted by HIV.

Approximately 366 individuals who self-identify as women presenting to a reproductive health clinic and an STI clinic in Duval County, Florida, will be recruited to the study in Aim 2, with 183 enrolled in each of the two phases. As the decision support tool is primarily focused on cisgender women, participants who do not identify as cisgender will be included in the study, but their study data will be analyzed separately. In the first phase of Aim 2 of the study, participants will receive care as usual at a clinic site after the trainings have been held for staff. In the second phase of Aim 2, participants will receive care at this same clinic that has been exposed to the training and will also view the HIV prevention DST. These participants will be compared to those recruited in Aim 1 of this study, in which participants accessed care from the same clinic prior to clinic-wide trainings, and half of participants viewed the HIV prevention DST.

In addition to these interventions, a subset of up to 80 participants (40 per phase) will be asked to allow audio-recording of their counseling sessions with a provider. A subset of up to 80 additional participants (40 per phase), all of whom self-identify as women of color, will be invited to complete one-hour, semi-structured interviews after their clinic visit about their experiences of using the DST, HIV prevention counseling, and decision making about PrEP. Those who participated in Aim 1, are not excluded from participating in Aim 2 however, they will not be eligible to participate in an interview.

Hypotheses:

  1. Women who receive care at a clinic following clinic-wide trainings on shared decision making and trauma informed care are more likely to initiate PrEP as compared to women who received care at the same clinic prior to training.
  2. In a clinic that received clinic-wide trainings in shared decision making and trauma informed care, women who use the HIV prevention decision support tool are more likely to initiate PrEP as compared to women who did not use the tool.
  3. Women who receive care at a clinic following clinic-wide training on shared decision making and trauma informed care and who also used the decision support tool are more likely to initiate PrEP as compared to women who receive care at the same clinic prior to training and did not use the tool.
  4. Women who receive care at a clinic following clinic-wide trainings on shared decision making and trauma informed care and who also used the decision support tool are more likely to initiate PrEP as compared to those who receive care at the same clinic prior to training and used the DST.
03

Conditions studied

  • Human Immunodeficiency Virus
  • Human Immunodeficiency Virus Transmission
  • Sexually Transmitted Diseases

Browse trials for

Keywords

  • Pre-exposure prophylaxis (PrEP)
  • HIV prevention behaviors
  • HIV prevention methods
  • HIV education
  • African American, Latina, women of color
  • Shared decision making
  • Shared decision-making
  • Decision making, shared
  • Trauma informed care
  • Trauma-informed care
  • Patient decision support
  • Patient decision aid
  • Public health clinic
  • Health department clinic
  • Southeastern U.S.
04

In context

Sexually Transmitted Diseases Reclassified

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

This study's enrollment of 141 is below the median of 449 across 426 interventional studies indexed under Sexually Transmitted Diseases.

Browse Sexually Transmitted Diseases studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.

Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.

Compared within Sexually Transmitted Diseases, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Self-identify as a woman (regardless of pregnancy status)
  • Age 18 years - 45 years
  • Not known to be living with (based on self-report)
  • English speaking
  • Interested in participating in the study

Exclusion criteria

Exclusion Criteria:

  • Unable to consent
  • Currently using PrEP
  • Those who were assigned male at birth and self-identify as a man
  • Unwilling to be contacted in 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Active comparator
    Care Post Clinic-Wide Trainings

    Participants in this arm will receive care in a clinic where providers and staff have been trained in shared decision making and trauma-informed care. Participants in this arm will not view the decision support tool in this phase.

    Other: Clinic-wide Trainings

  • Experimental
    Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)

    Participants in this arm will receive care in a clinic where providers and staff have been trained in shared decision making and trauma informed care, and receive the HIV prevention DST intervention immediately before their provider visit.

    Other: Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST)

Interventions

  • OtherClinic-wide Trainings

    The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.

  • OtherClinic-wide Trainings and HIV Prevention Decision Support Tool (DST)

    The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training. The DST is founded on principles of decision-science and will address barriers to PrEP delivery. The DST will present HIV prevention information through a tablet in the clinical setting. The tool provides information about vulnerabilities to HIV and core characteristics of different HIV prevention methods, and the opportunity to explore these characteristics in depth, including efficacy, safety and side effects. The tool emphasizes the highly variable and individual nature of baseline risk.

07

What researchers measure

Primary outcomes

  1. PrEP Prescriptions (As Measured by Chart Review)

    The number of participants who received a PrEP prescription within 3 months of their index clinical visit, obtained by chart extraction from the medical record. Outcome is dichotomous (Yes, received a PrEP prescription at initial visit/No, did not receive a PrEP prescription at initial visit).

    Time frame: 3 months post clinical visit

Secondary outcomes

  1. Number of Patients Reporting PrEP Use

    Patients will be contacted at follow-up and asked if they took PrEP in the past 3 months regardless of where it was obtained. Outcome is dichotomous ("Yes", initiated PrEP within 3 months of index visit/"No", did not initiate PrEP within 3 months of index visit)

    Time frame: 3 months post clinical visit

  2. Change in Patient-Perceived HIV Risk

    We will measure the change in HIV risk perception from pre- to post- index clinical visit. Response options include 4-point scale: 1 ("Not at all worried") to 4 ("Extremely worried"). Used to varify reports of change in worry over time. No independent estimates of effect performed.

    Time frame: Immediately preceding clinical visit compared to immediately following clinical visit

  3. Patient-Perceived HIV Risk

    Participants will be asked about how worried they are about getting HIV in the next 6 months. Response options include 4-point scale of 1 ("Not at all worried") to 4 ("Extremely worried").

    Time frame: Immediately post clinical visit

  4. PrEP Knowledge

    Percentage of participants selecting the correct response to three questions. Response options for each item are different. Higher score represents higher knowledge.

    Time frame: Immediately post clinical visit

  5. Decisional Conflict - Total Score

    16-item scale to measure decisional conflict. Response options range from 1-5 "strongly disagree" to "strongly agree". Mean score will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[no decisional conflict' to 100 \[extremely high decisional conflict\].Higher scores represent high decisional conflict.

    Time frame: Immediately post clinical visit

  6. Decisional Conflict - Uncertainty Subscore

    Three items from the Decisional Conflict scale will measure uncertainty: "I am clear about the best choice for me", "I feel sure about what to choose", and "the decision is easy for me to make". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely certain about best choice\] to 100 \[feels extremely uncertain about decision\]. Higher scores represent greater decision uncertainty.

    Time frame: Immediately post clinical visit

  7. Decisional Conflict - Informed Subscore

    Three items from the Decisional Conflict scale will measure the informed subscale: "I know which options are available to me", "I know the benefits of each option", and "I know the risks and side effects of each option". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely informed\] to 100 \[feels extremely uninformed\]. Higher scores represent a greater degree of feeling uninformed.

    Time frame: Immediately post clinical visit

  8. Decisional Conflict - Values Clarity Subscore

    Three items from the Decisional Conflict scale will measure values clarity: "I am clear about which benefits matter the most to me", "I am clear about which risks and side effects matter most to me", and "I am clear about which is more important to me (the benefits or the risks and side effects." Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely clear about personal values for benefits and risks/side effects\] to 100 \[feels extremely unclear about personal values\].

    Time frame: Immediately post clinical visit

  9. Decisional Conflict - Support Subscore

    Three items from the Decisional Conflict scale will measure support: "I have enough support from others to make a choice", "I am choosing without pressure from others", and "I have enough advice to make a choice". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely supported in decision making\] to 100 \[feels extremely unsupported in decision making\].

    Time frame: Immediately post clinical visit

  10. Decisional Conflict - Effective Decision Subscore

    Four items from the Decisional Conflict scale will measure effective decision: "I feel I have made an informed choice", "my decision shows what is important to me", "I expect to stick with my decision", and "I am satisfied with my decision". Response options range from 1-5 strongly disagree to strongly agree. Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[good decision\] to 100 \[bad decision\].

    Time frame: Immediately post clinical visit

  11. Interpersonal Quality of HIV Prevention Care

    Median score of 4-item scale. Derived from the Person-Centered Contraceptive Care measure developed by the PI. Response options consist of 5-point Likert scale: 1 ("strongly disagree") to 5 ("strongly agree"). Minimum possible score is 0 and maximum possible score is 20, with higher scores indicating better care. Scores will be dichotomized between 20 \[excellent interpersonal quality of care\] and less than 20 \[poor interpersonal quality of care\].

    Time frame: Immediately post clinical visit

  12. Interpersonal Quality of Health Services

    Median score of 4-item scale. Derived from the Person-Centered Contraceptive Counseling measure developed by the PI. Response options consist of 5-point Likert scale: 1 ("strongly disagree") to 5 ("strongly agree"). Minimum possible score is 0 and maximum possible score is 20, with higher scores indicating better care. Scores will be dichotomized between 20 \[excellent interpersonal quality of care\] and less than 20 \[poor interpersonal quality of care\]. This measure will exclude HIV prevention care and focus on other services offered.

    Time frame: Immediately post clinical visit

  13. Intention to Use Any HIV Prevention Method

    A one time, one item measure of plan to use HIV prevention method after the initial visit. Participants can select from "none", condoms, PrEP, PEP, treatment as prevention, regular HIV testing (inclusive of partner), "still thinking about my options", or other method.

    Time frame: Immediately post clinical visit

  14. Confidence in Decision to Use an HIV Prevention Method

    A one-time, one-item measure of certainty of plan to use HIV prevention after the initial visit. Participants can select from four options: 1 ("completely unsure"), 2 ("mostly unsure"), 3 ("mostly sure, but not 100%"), or 4 ("100% sure"). Presented as the percentage who reported being "fully sure" about HIV prevention method. Reporting here the percent who reported high confidence.

    Time frame: Immediately post clinical visit

  15. Satisfaction With Information Received About HIV Prevention

    Participants will be asked a one-time question regarding satisfaction with HIV prevention counseling. Response options include: 1 ("I was not given any information about HIV), 2 ("Very unsatisfied") 3 ("Somewhat unsatisfied), 4 ("Neither satisfied or unsatisfied"), 5 ("Somewhat satisfied") and 6 ("Very satisfied").

    Time frame: Immediately post clinical visit

  16. Perceived Quality of Information Received About HIV Prevention

    Participants will also be asked four questions about the perceived quality of the HIV prevention information patients received during their health care visit: 1) getting the information they needed, 2) the ease of understanding the information, 3) the trustworthiness of the information, and 4), the usefulness of the information. These questions will be asked of those who reported talking about HIV/HIV prevention during their visit with the healthcare provider or health educator OR those who talked to the healthcare provider or health educator about your chances of getting HIV. Response options are 1 to 5 "strongly disagree" to "strongly agree". Higher values indicate greater perceived quality. Recorded here are percentage of participants who "strongly agreed" with each statement.

    Time frame: Immediately post clinical visit

  17. Perceived Quality of Health Information Received

    Participants will also be asked four questions about the perceived quality of the health information patients received during their health care visit, excluding HIV prevention information: 1) getting the information they needed, 2) the ease of understanding the information, 3) the trustworthiness of the information, and 4), the usefulness of the information. These questions will be asked of those who reported talking about alcohol or drugs, intimate partner violence or abuse, pregnancy, contraception or birth control, STDs (not including HIV) or STD prevention, or other, during their visit with the healthcare provider or health educator. Response options are 1 to 5 "strongly disagree" to "strongly agree". Higher values indicate greater perceived quality.

    Time frame: Immediately post clinical visit

  18. Acceptability of HIV Prevention Methods

    Participants are asked to rate their preference for a method (even if they never used it). Participants can select from condoms, PrEP, PEP, treatment as prevention or other method. The option, "never heard of it" is also included. Options for this scale range from 0 ("Terrible method for me") to 10 ("Great method for me"). Recorded here is percent of participants who responded "great for me" to each item

    Time frame: Immediately post clinical visit

  19. Acceptability of the Decision Support Tool

    Participants who used the DST in the second phase of the study are asked four questions about their experiences using the DST (e.g., degree to which they got all the information they needed, found the information to be easy to understand, trust the information, and found information useful). Response items vary from strongly disagree to strongly agree. Reported here are the percentage of the participants who reported "strongly agree" to each item.

    Time frame: Immediately post clinical visit

  20. Perception of the Decision Support Tool

    Participants who used the DST in the second phase of the study will be asked about the degree to which they liked/disliked the tool. Response options vary: "I did not like it at all", "I somewhat liked it", "I somewhat liked it", or "I really liked it".

    Time frame: Immediately post clinical visit

  21. Satisfaction With the Decision Support Tool

    Participants who used the DST in the second phase of the study will be asked about the degree to which they are satisfied with the information in the tool. Response options vary from 1-5: "very unsatisfied" to "very satisfied".

    Time frame: Immediately post clinical visit

  22. Recommend the Decision Support Tool

    Participants who used the DST in the second phase of the study will be asked about whether they would recommend the decision support tool to a friend. Response options are "yes", "no", and "unsure".

    Time frame: Immediately post clinical visit

  23. Willingness to Use the Decision Support Tool at Future Visits

    Participants who used the DST in the second phase of the study will be asked about whether they would use the tool again if they returned to the clinic. Response options are "yes", "no", and "unsure"

    Time frame: Immediately post clinical visit

  24. HIV Prevention Method Use (Any Method - Planned or New Method)

    A self-reported measure of HIV prevention method use, including those who reported discontinuing the initial HIV prevention method(s) that were reported post-clinic visit. This item will be measured by a response of "yes" to any of the following questions: since your \[baseline\] visit, have you used....for HIV prevention - abstinence, condoms, PEP, PrEP, regular HIV testing, treatment as prevention, regular sexually transmitted disease (STD) testing, or other method. The outcome will be dichotomized to those who responded affirmatively vs other responses ("no"/"unsure").

    Time frame: 3 months post clinical visit

  25. HIV Prevention Method Continuation

    A self-reported measure of HIV prevention method continuation. This item will be measured by a response of "yes" to any of the following questions: are you still using - abstinence, condoms, PEP, PrEP, regular HIV testing, treatment as prevention, regular sexually transmitted disease (STD) testing, or other method. The outcome will be dichotomized to those who responded "yes" vs "no".

    Time frame: 3 months post clinical visit

08

Results

Posted Nov 4, 2026
Limitations and caveats
COVID-19 disrupted clinic operations, limiting HIV/PrEP counseling \& cancelling planned state-wide PrEP campaign for cisgender women. Staff turnover \& clinician departures altered patient flow \& lowered recruitment opportunities, requiring expansion of recruitment to an STI clinic not in Aim 1, \& prevented assurance that all staff had completed trainings. Findings may not be generalizable beyond publicly funded reproductive health \& STI clinics serving primarily English speaking populations.

Participant flow

Individuals will be handed a flyer about the study and eligibility criteria when they present to the front desk for check in. Interested individuals are then brought back to a private clinic room for an eligibility screening. Eligible individuals will then be enrolled into the study and randomized to either the control or intervention.

Participant flow — Overall Study
MilestoneCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Started8061
Completed4838
Not completed3223
Withdrew: Withdrawal by subject30
Withdrew: Lost to follow-up2923

Outcome measures

PrimaryPrEP Prescriptions (As Measured by Chart Review)

The number of participants who received a PrEP prescription within 3 months of their index clinical visit, obtained by chart extraction from the medical record. Outcome is dichotomous (Yes, received a PrEP prescription at initial visit/No, did not receive a PrEP prescription at initial visit).

Time frame:
3 months post clinical visit
Reported as:
Count of participants · Participants
PrEP Prescriptions (As Measured by Chart Review)
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
PrEP Prescriptions (As Measured by Chart Review)00
SecondaryNumber of Patients Reporting PrEP Use

Patients will be contacted at follow-up and asked if they took PrEP in the past 3 months regardless of where it was obtained. Outcome is dichotomous ("Yes", initiated PrEP within 3 months of index visit/"No", did not initiate PrEP within 3 months of index visit)

Time frame:
3 months post clinical visit
Reported as:
Count of participants · Participants
Number of Patients Reporting PrEP Use
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Number of Patients Reporting PrEP Use13
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Fisher Exact · p = 0.23 (threshold for significance: 0.05) · Odds ratio (or): 5.25 · 95% CI 0.399 to 68.945
SecondaryChange in Patient-Perceived HIV Risk

We will measure the change in HIV risk perception from pre- to post- index clinical visit. Response options include 4-point scale: 1 ("Not at all worried") to 4 ("Extremely worried"). Used to varify reports of change in worry over time. No independent estimates of effect performed.

Time frame:
Immediately preceding clinical visit compared to immediately following clinical visit
Reported as:
Count of participants · Participants
Change in Patient-Perceived HIV Risk
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
No change6853
Increased worry10
Decreased worry85
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Fisher Exact · p = 1.00threshold for significance: \<0.05
SecondaryPatient-Perceived HIV Risk

Participants will be asked about how worried they are about getting HIV in the next 6 months. Response options include 4-point scale of 1 ("Not at all worried") to 4 ("Extremely worried").

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Patient-Perceived HIV Risk
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Not at all worried5947
A little worried146
Very worried32
Extremely worried23
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.57 · Odds ratio (or): 0.482 · 95% CI 0.129 to 1.791variable transformed into binary variable of not at all worry v. worried at all due to skew
SecondaryPrEP Knowledge

Percentage of participants selecting the correct response to three questions. Response options for each item are different. Higher score represents higher knowledge.

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
PrEP Knowledge
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
PrEP is a daily pill to prevent HIV3229
PrEP is for all adults5350
PrEP will not work if taken once a week3432
PrEP does not prevent STDs other than HIV3432
PrEP side effects do not last forever2031
A baby could be born to HIV discordant parents without transmitting HIV2927
There is medication that you can take after sex to prevent HIV (PEP)2539
PrEP efficacy is > 95%4530
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.33 (threshold for significance \<0.05) · Odds ratio (or): 1.406 · 95% CI 0.708 to 2.792
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.02 (threshold for significance \<0.05) · Odds ratio (or): 2.830 · 95% CI 1.164 to 6.882
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.01 (threshold for significance \<0.05) · Odds ratio (or): 2.535 · 95% CI 1.251 to 5.138
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.21 (threshold for significance \<0.05) · Odds ratio (or): 1.557 · 95% CI 0.784 to 3.089
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = <0.01 (the threshold for significance \<0.05) · Odds ratio (or): 3.272 · 95% CI 1.585 to 6.756
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.30 (threshold for significance \<0.05) · Odds ratio (or): 1.442 · 95% CI 0.722 to 2.879
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = <0.01 (threshold for significance \<0.05) · Odds ratio (or): 4.269 · 95% CI 2.064 to 8.310
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.44 (threshold for significance \<0.05) · Odds ratio (or): 0.762 · 95% CI 0.384 to 1.513
SecondaryDecisional Conflict - Total Score

16-item scale to measure decisional conflict. Response options range from 1-5 "strongly disagree" to "strongly agree". Mean score will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[no decisional conflict' to 100 \[extremely high decisional conflict\].Higher scores represent high decisional conflict.

Time frame:
Immediately post clinical visit
Reported as:
Median · units on a scale
Decisional Conflict - Total Score
units on a scaleCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Decisional Conflict - Total Score25 (0 to 27)2 (0 to 25)
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.002 · Odds ratio (or): 1.941 · 95% CI 0.962 to 3.917due to skew and distribution of responses, DCS transformed into binary variable of no conflict versus any conflict for analysis
SecondaryDecisional Conflict - Uncertainty Subscore

Three items from the Decisional Conflict scale will measure uncertainty: "I am clear about the best choice for me", "I feel sure about what to choose", and "the decision is easy for me to make". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely certain about best choice\] to 100 \[feels extremely uncertain about decision\]. Higher scores represent greater decision uncertainty.

Time frame:
Immediately post clinical visit
Reported as:
Median · units on a scale
Decisional Conflict - Uncertainty Subscore
units on a scaleCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Decisional Conflict - Uncertainty Subscore25 (0 to 25)0 (0 to 25)
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = <0.01 (threshold for significance \<0.05) · Odds ratio (or): 2.564 · 95% CI 1.272 to 5.167transformed into binary variable of no conflict versus any conflict due to data skew
SecondaryDecisional Conflict - Informed Subscore

Three items from the Decisional Conflict scale will measure the informed subscale: "I know which options are available to me", "I know the benefits of each option", and "I know the risks and side effects of each option". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely informed\] to 100 \[feels extremely uninformed\]. Higher scores represent a greater degree of feeling uninformed.

Time frame:
Immediately post clinical visit
Reported as:
Median · units on a scale
Decisional Conflict - Informed Subscore
units on a scaleCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Decisional Conflict - Informed Subscore25 (0 to 25)0 (0 to 25)
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.003 (theshold for significance 0.05) · Odds ratio (or): 2.102 · 95% CI 1.051 to 4.204variable transformed into binary variable of no conflict versus any conflict for analysis due to skew in distribution
SecondaryDecisional Conflict - Values Clarity Subscore

Three items from the Decisional Conflict scale will measure values clarity: "I am clear about which benefits matter the most to me", "I am clear about which risks and side effects matter most to me", and "I am clear about which is more important to me (the benefits or the risks and side effects." Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely clear about personal values for benefits and risks/side effects\] to 100 \[feels extremely unclear about personal values\].

Time frame:
Immediately post clinical visit
Reported as:
Median · units on a scale
Decisional Conflict - Values Clarity Subscore
units on a scaleCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Decisional Conflict - Values Clarity Subscore25 (0 to 33)0 (0 to 25)
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = <0.001 (threshold for significance 0.05) · Odds ratio (or): 2.792 · 95% CI 1.134 to 4.579
SecondaryDecisional Conflict - Support Subscore

Three items from the Decisional Conflict scale will measure support: "I have enough support from others to make a choice", "I am choosing without pressure from others", and "I have enough advice to make a choice". Response options range from 1-5 "strongly disagree" to "strongly agree". Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[feels extremely supported in decision making\] to 100 \[feels extremely unsupported in decision making\].

Time frame:
Immediately post clinical visit
Reported as:
Median · units on a scale
Decisional Conflict - Support Subscore
units on a scaleCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Decisional Conflict - Support Subscore25 (0 to 25)0 (0 to 25)
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.02 (threshold for significance 0.05) · Odds ratio (or): 1.826 · 95% CI 0.917 to 3.638variable transformed into binary variable of no conflict versus any conflict for analysis due to skew
SecondaryDecisional Conflict - Effective Decision Subscore

Four items from the Decisional Conflict scale will measure effective decision: "I feel I have made an informed choice", "my decision shows what is important to me", "I expect to stick with my decision", and "I am satisfied with my decision". Response options range from 1-5 strongly disagree to strongly agree. Items will be reverse-coded. Mean scores will be calculated, subtracted by 1, and multiplied by 25; scores range from 0 \[good decision\] to 100 \[bad decision\].

Time frame:
Immediately post clinical visit
Reported as:
Median · units on a scale
Decisional Conflict - Effective Decision Subscore
units on a scaleCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Decisional Conflict - Effective Decision Subscore19 (0 to 25)0 (0 to 25)
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.02 (threshold for significance) · Odds ratio (or): 1.760 · 95% CI 0.884 to 3.503variable transformed into binary variable of no conflict versus any conflict for analysis due to skew
SecondaryInterpersonal Quality of HIV Prevention Care

Median score of 4-item scale. Derived from the Person-Centered Contraceptive Care measure developed by the PI. Response options consist of 5-point Likert scale: 1 ("strongly disagree") to 5 ("strongly agree"). Minimum possible score is 0 and maximum possible score is 20, with higher scores indicating better care. Scores will be dichotomized between 20 \[excellent interpersonal quality of care\] and less than 20 \[poor interpersonal quality of care\].

Time frame:
Immediately post clinical visit
Reported as:
Median · units on a scale
Interpersonal Quality of HIV Prevention Care
units on a scaleCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Interpersonal Quality of HIV Prevention Care20 (15 to 20)20 (16 to 20)
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.18 (threshold for significance \<0.05) · Odds ratio (or): 1.923 · 95% CI 0.846 to 4.373
SecondaryInterpersonal Quality of Health Services

Median score of 4-item scale. Derived from the Person-Centered Contraceptive Counseling measure developed by the PI. Response options consist of 5-point Likert scale: 1 ("strongly disagree") to 5 ("strongly agree"). Minimum possible score is 0 and maximum possible score is 20, with higher scores indicating better care. Scores will be dichotomized between 20 \[excellent interpersonal quality of care\] and less than 20 \[poor interpersonal quality of care\]. This measure will exclude HIV prevention care and focus on other services offered.

Time frame:
Immediately post clinical visit
Reported as:
Median · units on a scale
Interpersonal Quality of Health Services
units on a scaleCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Interpersonal Quality of Health Services20 (16 to 20)20 (16 to 20)
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.59 (significance threshold of 0.05) · Odds ratio (or): 0.211 · 95% CI 0.021 to 2.094
SecondaryIntention to Use Any HIV Prevention Method

A one time, one item measure of plan to use HIV prevention method after the initial visit. Participants can select from "none", condoms, PrEP, PEP, treatment as prevention, regular HIV testing (inclusive of partner), "still thinking about my options", or other method.

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Intention to Use Any HIV Prevention Method
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Intention to Use Any HIV Prevention Method7357
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.63 (threshold for significance 0.05)
SecondaryConfidence in Decision to Use an HIV Prevention Method

A one-time, one-item measure of certainty of plan to use HIV prevention after the initial visit. Participants can select from four options: 1 ("completely unsure"), 2 ("mostly unsure"), 3 ("mostly sure, but not 100%"), or 4 ("100% sure"). Presented as the percentage who reported being "fully sure" about HIV prevention method. Reporting here the percent who reported high confidence.

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Confidence in Decision to Use an HIV Prevention Method
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
PrEP910
Abstinence3127
Condoms4945
PEP912
Regular HIV testing5349
Regular STD testing5849
Treatment as prevention2121
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.15 (significance threshold of 0.05) · Phi coefficient: 0.315phi coefficient calculated due to small sample size. variable transformed into highest binary of confidence versus lower confidence due to data skew
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.40 (significance threshold at \<0.05) · Phi coefficient: 0.107phi coefficient calculated due to small sample size. variable transformed into highest binary of confidence versus lower confidence due to data skew
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.11 (significance threshold at \<0.05) · Phi coefficient: 0.321phi coefficient calculated due to small sample size. variable transformed into highest binary of confidence versus lower confidence due to data skew
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.11 (significance threshold 0.05) · Odds ratio (or): 1.541 · 95% CI 0.349 to 6.790variable transformed into highest binary of confidence versus lower confidence due to data skew
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.98 (significance threshold of 0.05) · Odds ratio (or): 1.056 · 95% CI 0.269 to 4.150variable transformed into highest binary of confidence versus lower confidence due to data skew
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.21 (significance threshold of \<0.05) · Phi coefficient: 0.185phi coefficient calculated due to small sample size. variable transformed into highest binary of confidence versus lower confidence due to data skew
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.08 (significance threshold of 0.05) · Odds ratio (or): 2.571 · 95% CI 0.857 to 7.712phi coefficient calculated due to small sample size. variable transformed into highest binary of confidence versus lower confidence due to data skew
SecondarySatisfaction With Information Received About HIV Prevention

Participants will be asked a one-time question regarding satisfaction with HIV prevention counseling. Response options include: 1 ("I was not given any information about HIV), 2 ("Very unsatisfied") 3 ("Somewhat unsatisfied), 4 ("Neither satisfied or unsatisfied"), 5 ("Somewhat satisfied") and 6 ("Very satisfied").

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Satisfaction With Information Received About HIV Prevention
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
I was not given any information101
Very unsatisfied13
Neither satisfied or unsatisfied32
Somewhat satisfied62
Very satisfied5850
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Wilcoxon (Mann-Whitney) · p = 0.07 (significance threshold \<0.05) · Odds ratio (or): 2.155 · 95% CI 0.874 to 5.317variable transformed for analysis into binary of very satisfied versus less satisfied due to skew
SecondaryPerceived Quality of Information Received About HIV Prevention

Participants will also be asked four questions about the perceived quality of the HIV prevention information patients received during their health care visit: 1) getting the information they needed, 2) the ease of understanding the information, 3) the trustworthiness of the information, and 4), the usefulness of the information. These questions will be asked of those who reported talking about HIV/HIV prevention during their visit with the healthcare provider or health educator OR those who talked to the healthcare provider or health educator about your chances of getting HIV. Response options are 1 to 5 "strongly disagree" to "strongly agree". Higher values indicate greater perceived quality. Recorded here are percentage of participants who "strongly agreed" with each statement.

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Perceived Quality of Information Received About HIV Prevention
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
I got all the information I needed2732
Information was easy to understand2832
Trusted the information given3133
Found the information useful2931
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.08 (significance threshold of 0.05) · Odds ratio (or): 2.607 · 95% CI 1.175 to 5.784Given skew of data, outcome was dichotomized between "strongly agree" responses and all others.
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.23 (significance threshold of 0.05) · Odds ratio (or): 2.438 · 95% CI 1.100 to 5.404Given skew of data, outcome was dichotomized between "strongly agree" responses and all others.
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.18 (significance threshold of 0.05) · Odds ratio (or): 2.205 · 95% CI 0.986 to 4.929Given skew of data, outcome was dichotomized between "strongly agree" responses and all others.
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.29 (significance threshold of 0.05) · Odds ratio (or): 2.071 · 95% CI 0.942 to 4.552Given skew of data, outcome was dichotomized between "strongly agree" responses and all others.
SecondaryPerceived Quality of Health Information Received

Participants will also be asked four questions about the perceived quality of the health information patients received during their health care visit, excluding HIV prevention information: 1) getting the information they needed, 2) the ease of understanding the information, 3) the trustworthiness of the information, and 4), the usefulness of the information. These questions will be asked of those who reported talking about alcohol or drugs, intimate partner violence or abuse, pregnancy, contraception or birth control, STDs (not including HIV) or STD prevention, or other, during their visit with the healthcare provider or health educator. Response options are 1 to 5 "strongly disagree" to "strongly agree". Higher values indicate greater perceived quality.

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Perceived Quality of Health Information Received
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Got the information I needed4331
The information was easy to understand4330
I trusted the information4231
The information felt useful to me4331
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.59 (significance threshold of 0.05) · Odds ratio (or): 1.229 · 95% CI 0.577 to 2.619Given skew of data, outcome was dichotomized between "strongly agree" responses and all others.
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.76 (significance threshold of 0.05) · Odds ratio (or): 1.124 · 95% CI 0.531 to 2.381Given skew of data, outcome was dichotomized between "strongly agree" responses and all others.
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.49 (significance threshold of 0.05) · Odds ratio (or): 1.302 · 95% CI 0.612 to 2.770Given skew of data, outcome was dichotomized between "strongly agree" responses and all others.
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.59 (significance threshold of 0.05) · Odds ratio (or): 1.229 · 95% CI 0.577 to 2.619Given skew of data, outcome was dichotomized between "strongly agree" responses and all others.
SecondaryAcceptability of HIV Prevention Methods

Participants are asked to rate their preference for a method (even if they never used it). Participants can select from condoms, PrEP, PEP, treatment as prevention or other method. The option, "never heard of it" is also included. Options for this scale range from 0 ("Terrible method for me") to 10 ("Great method for me"). Recorded here is percent of participants who responded "great for me" to each item

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Acceptability of HIV Prevention Methods
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Abstinence3020
Condoms2823
PEP1516
PrEP1514
HIV testing3832
STD testing4030
Treatment as prevention2420
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.63 (significance threshold of 0.05) · Odds ratio (or): 0.842 · 95% CI 0.415 to 1.709
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.79 (significance threshold of 0.05) · Odds ratio (or): 1.110 · 95% CI 0.552 to 2.232
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.25 (significance threshold of 0.05) · Odds ratio (or): 1.600 · 95% CI 0.715 to 3.580
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.49 (significance threshold of 0.05) · Odds ratio (or): 1.336 · 95% CI 0.586 to 3.046
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.55 (significance threshold of 0.05) · Odds ratio (or): 1.231 · 95% CI 0.622 to 2.434
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.92 (significance threshold of 0.92) · Odds ratio (or): 0.967 · 95% CI 0.489 to 1.909
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.65 (significance threshold of 0.05) · Odds ratio (or): 1.184 · 95% CI 0.574 to 2.443
SecondaryAcceptability of the Decision Support Tool

Participants who used the DST in the second phase of the study are asked four questions about their experiences using the DST (e.g., degree to which they got all the information they needed, found the information to be easy to understand, trust the information, and found information useful). Response items vary from strongly disagree to strongly agree. Reported here are the percentage of the participants who reported "strongly agree" to each item.

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Acceptability of the Decision Support Tool
ParticipantsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
I got all of the information I need from the DST34
Information on the DST was easy to understand37
I trusted the information on the DST37
The information felt helpful to me33
SecondaryPerception of the Decision Support Tool

Participants who used the DST in the second phase of the study will be asked about the degree to which they liked/disliked the tool. Response options vary: "I did not like it at all", "I somewhat liked it", "I somewhat liked it", or "I really liked it".

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Perception of the Decision Support Tool
ParticipantsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
I did not like it all1
I somewhat liked it6
I really liked it52
SecondarySatisfaction With the Decision Support Tool

Participants who used the DST in the second phase of the study will be asked about the degree to which they are satisfied with the information in the tool. Response options vary from 1-5: "very unsatisfied" to "very satisfied".

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Satisfaction With the Decision Support Tool
ParticipantsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Very unsatisfied1
Somewhat satisfied6
Very satisfied52
SecondaryRecommend the Decision Support Tool

Participants who used the DST in the second phase of the study will be asked about whether they would recommend the decision support tool to a friend. Response options are "yes", "no", and "unsure".

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Recommend the Decision Support Tool
ParticipantsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Would recommend DST58
Would not recommend DST1
SecondaryWillingness to Use the Decision Support Tool at Future Visits

Participants who used the DST in the second phase of the study will be asked about whether they would use the tool again if they returned to the clinic. Response options are "yes", "no", and "unsure"

Time frame:
Immediately post clinical visit
Reported as:
Count of participants · Participants
Willingness to Use the Decision Support Tool at Future Visits
ParticipantsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
Yes47
No8
Unsure4
SecondaryHIV Prevention Method Use (Any Method - Planned or New Method)

A self-reported measure of HIV prevention method use, including those who reported discontinuing the initial HIV prevention method(s) that were reported post-clinic visit. This item will be measured by a response of "yes" to any of the following questions: since your \[baseline\] visit, have you used....for HIV prevention - abstinence, condoms, PEP, PrEP, regular HIV testing, treatment as prevention, regular sexually transmitted disease (STD) testing, or other method. The outcome will be dichotomized to those who responded affirmatively vs other responses ("no"/"unsure").

Time frame:
3 months post clinical visit
Reported as:
Count of participants · Participants
HIV Prevention Method Use (Any Method - Planned or New Method)
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
HIV Prevention Method Use (Any Method - Planned or New Method)3935
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.21 (significance threshold of 0.05) · Odds ratio (or): 2.692 · 95% CI 0.674 to 10.745
SecondaryHIV Prevention Method Continuation

A self-reported measure of HIV prevention method continuation. This item will be measured by a response of "yes" to any of the following questions: are you still using - abstinence, condoms, PEP, PrEP, regular HIV testing, treatment as prevention, regular sexually transmitted disease (STD) testing, or other method. The outcome will be dichotomized to those who responded "yes" vs "no".

Time frame:
3 months post clinical visit
Reported as:
Count of participants · Participants
HIV Prevention Method Continuation
ParticipantsCare Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)
HIV Prevention Method Continuation3733
Statistical analysis
  • Care Post Clinic-Wide Trainings vs Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST) · Chi-squared · p = 0.28 (significance threshold of 0.05) · Odds ratio (or): 1.962 · 95% CI 0.617 to 6.238

Adverse events

Collected over from enrollment until end of follow-up, up to 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Care Post Clinic-Wide Trainings0/80 (0%)0/80 (0%)0/80 (0%)
Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)0/61 (0%)0/61 (0%)0/61 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)Care Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)Total
18-24 years old222042
25-29 years old141226
30-34 years old181028
35-44 years old231639
Not reported336
Sex: Female, Male
Sex: Female, Male(Participants)Care Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)Total
Female8061141
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Care Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)Total
American Indian or Alaska Native101
Asian224
Native Hawaiian or Other Pacific Islander011
Black or African American5746103
White11718
More than one race6410
Unknown or Not Reported314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Care Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)Total
Hispanic or Latino14418
Not Hispanic or Latino6454118
Unknown or Not Reported235
Parental Education
Parental Education(Participants)Care Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)Total
8th grade or less358
Some high school101525
High school graduate392261
Some college17926
4-yer college graduate549
More than 4 year college completed437
Not reported235
Yearly income
Yearly income(Participants)Care Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)Total
Less than $10,000222446
$10,000-$19,99922830
$20,000-$29,99913821
$30,000-$39,999111021
$40,000-$49,999437
$50,000-$74,999549
$75,000-$99,999112
Not reported235
Educational attainment
Educational attainment(Participants)Care Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)Total
8th grade or less314
Still in high school235
Less than a high school diploma628
High school graduate343367
Some college261541
4-year college graduate415
More than 4-year college336
Not reported235
Housing status
Housing status(Participants)Care Post Clinic-Wide TrainingsCare Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)Total
Rent or own514192
Living in a shelter000
Living in a treatment facility011
Staying with friends261642
Staying in a hotel101
Missing235

18 further baseline measures are reported on the registry.

09

Study locations

1 site
  • Florida Department of Health, Duval County
    Jacksonville, Florida 32211, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Oct 2024, 22 months.

Results were first posted in Nov 2026, 2 years after primary completion. A results delay was requested in Sep 2025.

Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's 22 months is below that.

Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Nov 17, 2022
StartActual
Dec 2, 2022
Primary completionActual
Oct 8, 2024
CompletionActual
Nov 1, 2024
Results delay requested
Sep 24, 2025
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Interventions
Removed Standard Care with the HIV Prevention Decision Support Tool (DST). Arms removed: Standard Care without the HIV Prevention Decision Support Tool (DST)·Standard care with the HIV Prevention Decision Support Tool (DST)
Nov 4, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time framePrEP Prescriptions (As Measured by Chart Review)3 months post baseline visit → 3 months post clinical visit
  • DescriptionPrEP Prescriptions (As Measured by Chart Review): how it is measured was reworded
Nov 4, 2026
Documents
Secondary outcomes
6 edited, 19 time frame changed, 5 description edited, 2 more
What changed in the outcomes
  • EditedChange in Patient-Perceived HIV riskRiskTime frame: Baseline, pre-intervention compared to immediately post baseline visit → Immediately preceding clinical visit compared to immediately following clinical visit
  • EditedPatient-Perceived HIV riskRiskTime frame: Immediately post baseline visit → Immediately post clinical visit
  • EditedSatisfaction withWith Information Received aboutAbout HIV PreventionTime frame: Immediately post baseline visit → Immediately post clinical visit
  • EditedPerceived Quality of Information Received aboutAbout HIV PreventionTime frame: Immediately post baseline visit → Immediately post clinical visit
  • EditedSatisfaction withWith the Decision Support ToolTime frame: Immediately post baseline visit → Immediately post clinical visit
  • EditedHIV Prevention Method Use (any methodAny Method - plannedPlanned or new methodNew Method)Time frame: 3 months post baseline visit → 3 months post clinical visit
  • Time frameNumber of Patients Reporting PrEP Use3 months post baseline visit → 3 months post clinical visit
  • Time framePrEP KnowledgeImmediately post baseline visit → Immediately post clinical visit
  • Time frameDecisional Conflict - Total ScoreImmediately post baseline visit → Immediately post clinical visit
  • Time frameDecisional Conflict - Uncertainty SubscoreImmediately post baseline visit → Immediately post clinical visit
  • Time frameDecisional Conflict - Informed SubscoreImmediately post baseline visit → Immediately post clinical visit
  • Time frameDecisional Conflict - Values Clarity SubscoreImmediately post baseline visit → Immediately post clinical visit
  • Time frameDecisional Conflict - Support SubscoreImmediately post baseline visit → Immediately post clinical visit
  • Time frameDecisional Conflict - Effective Decision SubscoreImmediately post baseline visit → Immediately post clinical visit
  • Time frameInterpersonal Quality of HIV Prevention CareImmediately post baseline visit → Immediately post clinical visit
  • Time frameInterpersonal Quality of Health ServicesImmediately post baseline visit → Immediately post clinical visit
  • Time frameIntention to Use Any HIV Prevention MethodImmediately post baseline visit → Immediately post clinical visit
  • Time frameConfidence in Decision to Use an HIV Prevention MethodImmediately post baseline visit → Immediately post clinical visit
  • Time framePerceived Quality of Health Information ReceivedImmediately post baseline visit → Immediately post clinical visit
  • Time frameAcceptability of HIV Prevention MethodsImmediately post baseline visit → Immediately post clinical visit
  • Time frameAcceptability of the Decision Support ToolImmediately post baseline visit → Immediately post clinical visit
  • Time framePerception of the Decision Support ToolImmediately post baseline visit → Immediately post clinical visit
  • Time frameRecommend the Decision Support ToolImmediately post baseline visit → Immediately post clinical visit
  • Time frameWillingness to Use the Decision Support Tool at Future VisitsImmediately post baseline visit → Immediately post clinical visit
  • Time frameHIV Prevention Method Continuation3 months post baseline visit → 3 months post clinical visit
  • DescriptionAcceptability of HIV Prevention Methods: how it is measured was reworded
  • DescriptionAcceptability of the Decision Support Tool: how it is measured was reworded
  • DescriptionConfidence in Decision to Use an HIV Prevention Method: how it is measured was reworded
  • DescriptionInterpersonal Quality of HIV Prevention Care: how it is measured was reworded
  • DescriptionInterpersonal Quality of Health Services: how it is measured was reworded
  • …and 2 more, on the record history on ClinicalTrials.gov ↗
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time framePrEP Prescriptions (As Measured by Chart Review)3 months post baseline visit → 3 months post clinical visit
    • DescriptionPrEP Prescriptions (As Measured by Chart Review): how it is measured was reworded
    Secondary outcomes 6 edited, 19 time frame changed, 5 description edited, 2 more
    What changed in the outcomes
    • EditedChange in Patient-Perceived HIV riskRiskTime frame: Baseline, pre-intervention compared to immediately post baseline visit → Immediately preceding clinical visit compared to immediately following clinical visit
    • EditedPatient-Perceived HIV riskRiskTime frame: Immediately post baseline visit → Immediately post clinical visit
    • EditedSatisfaction withWith Information Received aboutAbout HIV PreventionTime frame: Immediately post baseline visit → Immediately post clinical visit
    • EditedPerceived Quality of Information Received aboutAbout HIV PreventionTime frame: Immediately post baseline visit → Immediately post clinical visit
    • EditedSatisfaction withWith the Decision Support ToolTime frame: Immediately post baseline visit → Immediately post clinical visit
    • EditedHIV Prevention Method Use (any methodAny Method - plannedPlanned or new methodNew Method)Time frame: 3 months post baseline visit → 3 months post clinical visit
    • Time frameNumber of Patients Reporting PrEP Use3 months post baseline visit → 3 months post clinical visit
    • Time framePrEP KnowledgeImmediately post baseline visit → Immediately post clinical visit
    • Time frameDecisional Conflict - Total ScoreImmediately post baseline visit → Immediately post clinical visit
    • Time frameDecisional Conflict - Uncertainty SubscoreImmediately post baseline visit → Immediately post clinical visit
    • Time frameDecisional Conflict - Informed SubscoreImmediately post baseline visit → Immediately post clinical visit
    • Time frameDecisional Conflict - Values Clarity SubscoreImmediately post baseline visit → Immediately post clinical visit
    • Time frameDecisional Conflict - Support SubscoreImmediately post baseline visit → Immediately post clinical visit
    • Time frameDecisional Conflict - Effective Decision SubscoreImmediately post baseline visit → Immediately post clinical visit
    • Time frameInterpersonal Quality of HIV Prevention CareImmediately post baseline visit → Immediately post clinical visit
    • Time frameInterpersonal Quality of Health ServicesImmediately post baseline visit → Immediately post clinical visit
    • Time frameIntention to Use Any HIV Prevention MethodImmediately post baseline visit → Immediately post clinical visit
    • Time frameConfidence in Decision to Use an HIV Prevention MethodImmediately post baseline visit → Immediately post clinical visit
    • Time framePerceived Quality of Health Information ReceivedImmediately post baseline visit → Immediately post clinical visit
    • Time frameAcceptability of HIV Prevention MethodsImmediately post baseline visit → Immediately post clinical visit
    • Time frameAcceptability of the Decision Support ToolImmediately post baseline visit → Immediately post clinical visit
    • Time framePerception of the Decision Support ToolImmediately post baseline visit → Immediately post clinical visit
    • Time frameRecommend the Decision Support ToolImmediately post baseline visit → Immediately post clinical visit
    • Time frameWillingness to Use the Decision Support Tool at Future VisitsImmediately post baseline visit → Immediately post clinical visit
    • Time frameHIV Prevention Method Continuation3 months post baseline visit → 3 months post clinical visit
    • DescriptionAcceptability of HIV Prevention Methods: how it is measured was reworded
    • DescriptionAcceptability of the Decision Support Tool: how it is measured was reworded
    • DescriptionConfidence in Decision to Use an HIV Prevention Method: how it is measured was reworded
    • DescriptionInterpersonal Quality of HIV Prevention Care: how it is measured was reworded
    • DescriptionInterpersonal Quality of Health Services: how it is measured was reworded
    • …and 2 more, on the record history on ClinicalTrials.gov ↗
    Interventions Removed Standard Care with the HIV Prevention Decision Support Tool (DST). Arms removed: Standard Care without the HIV Prevention Decision Support Tool (DST)·Standard care with the HIV Prevention Decision Support Tool (DST)
    + 4 other changes: index terms, verification date, description and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05619497
Responsible party
Sponsor
First posted
Nov 17, 2022
Start date
Dec 2, 2022
Primary completion
Oct 8, 2024
Completion
Nov 1, 2024
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Christine Dehlendorf, MD, MAS
principal investigator · University of California, San Francisco
Akilah Pope, MD
principal investigator · Florida Department of Health, Duval County

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion